Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$1.71 USD
-0.02 (-1.16%)
Updated Jan 14, 2025 04:00 PM ET
After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QNCX 1.71 -0.02(-1.16%)
Will QNCX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for QNCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNCX
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNCX
Quince Therapeutics management to meet with Maxim Group
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Quince Therapeutics initiated with a Buy at Brookline
Quince Therapeutics initiated with bullish view at Brookline, here's why
Quince Therapeutics management to meet with Maxim Group